Angiogenic markers in canine lymphoma tissues do not predict survival times in chemotherapy treated dogs

Research in Veterinary Science

Volumn 92, Issue 3, 2012, Pages 444-450

  Wolfesberger, B ^a   Tonar, Z ^b,c   Fuchs Baumgartinger, A ^a   Walter, I ^a   Skalicky, M ^a   Witter, K ^a   Thalhammer, J G ^a   Pagitz, M ^a   Kleiter, M ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF WEST BOHEMIA   (Czech Republic)

Author keywords

Canine lymphoma; Microvessel density; Overall survival time; Receptors; Vascular endothelial growth factor

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PARAMETERS; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOG; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHOMA; MICROVASCULATURE; MICROVESSEL DENSITY; NONHUMAN; OVERALL SURVIVAL; PREDICTION; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; LYMPHOMA; MALE; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

CANIS FAMILIARIS;

EID: 84859104260     PISSN: 00345288     EISSN: 15322661     Source Type: Journal    
DOI: 10.1016/j.rvsc.2011.04.018     Document Type: Article

References (53)

1. Al-Dissi A.N., Haines D.M., Singh B., Kidney B.A. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas. Veterinary Pathology 2007, 44:823-830.
2. Bairey O., Zimra Y., Kaganovsky E., Shaklai M., Okon E., Rabizadeh E. Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas. Medical Oncology 2000, 17:314-318.
3. Carter R.F., Valli V.E., Lumsden J.H. The cytology, histology and prevalence of cell types in canine lymphoma classified according to the National Cancer Institute Working Formulation. Canadian Journal of Veterinary Research 1986, 50:154-164.
4. Cohen M.H., Gootenberg J., Keegan P., Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007, 12:356-361.
5. De Jong J.S., van Diest P.J., van der Valk P., Baak J.P. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: an inventory in search of autocrine and paracrine loops. Journal of Pathology 1998, 184:44-52.
6. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., Moore M.W. Heterozygous embryonic lethality by targeted inactivation of the VEGF gene. Nature 1996, 380:439-442.
7. Ferrara N., Gerber H.P., Le Couter J. The biology of VEGF and its receptors. Nature Medicine 2003, 9:669-676.
8. Finn R.S., Zhu A.X. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Review of Anticancer Therapy 2009, 9:503-509.
9. Fleurnel-Fleury C., Magnol J.P., Bricaire P., Marchal T., Chabanne L., Delverdier A., Bryon P.A., Felman P. Cytohistological and immunological classification of canine malignant lymphomas: comparison with human non-Hodgkin's lymphomas. Journal of Comparative Pathology 1997, 117:35-59.
10. Folkman J. Tumor angiogenesis: therapeutic implications. The New England Journal of Medicine 1971, 285:1182-1186.
11. Fox S.B., Harris A.L. Histological quantitation of tumour angiogenesis. Acta Pathologica, Microbiologica et Immunologica Scandinavica 2004, 112:413-430.
12. Ganjoo K.N., An C.S., Robertson M.J., Gordon L.I., Sen J.A., Weisenbach J., Li S., Weller E.A., Orazi A., Horning S.J. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leukemia and Lymphoma 2006, 47:998-1005.
13. Ganjoo K.N., Moore A.M., Orazi A., Sen J.A., Johnson C.S., An C.S. The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. Journal of Cancer Research and Clinical Oncology 2008, 134:381-387.
14. Garrett L.D., Thamm D.H., Chun R., Dudley R., Vail D.M. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 2002, 16:704-709.
15. Gentilini F., Calzolari C., Turba M.E., Agnoli C., Fava D., Forni M., Bergamini P.F. Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs. Leukemia Research 2005, 29:1263-1269.
16. Gratzinger D., Zhao S., Marinelli R.J., Kapp A.V., Tibshirani R.J., Hammer A.S., Hamilton-Dutoit S., Natkunam Y. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma substages. American Journal of Pathology 2007, 170:1362-1369.
17. Gratzinger D., Zhao S., Tibshirani R.J., His E.D., Hans C.P., Pohlman B., Bast M., Avigdor A., Schiby G., Nagler A., Byrne G.E., Lossos I.S., Natkunam Y. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Laboratory Investigation 2008, 88:38-47.
18. Gratzinger D., Advani R., Zhao S., Talreja N., Tibshirani R.J., Shyam R., Horning S., Sehn L.H., Farinha P., Briones J., Lossos I.S., Gascoyne R.D., Natkunam Y. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). British Journal of Haematology 2010, 148:235-244.
19. Gundersen H.J.G. Notes on the estimation of the numerical density of arbitrary particles: the edge effect. Journal of Microscopy 1977, 111:219-223.
20. Hazar B., Paydas S., Zorludemir S., Sahin B., Tuncer I. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leukemia and Lymphoma 2003, 44:2089-2093.
21. Hlatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. Journal of the National Cancer Institute 2002, 94:883-893.
22. Hosoya K., Kissberth W.C., Lord L.K., Alvarez F.J., Lara-Garcia A., Kosarek C.E., London C.A., Couto C.G. Comparison of COAP and UW-19 protocols for dog with multicentric lymphoma. Journal of Veterinary Internal Medicine 2007, 21:1355-1363.
23. Jørgensen J.M., Sørensen F.B., Bendix K., Nielsen J.L., Olsen M.L., Funder A.M., d'Amore F. Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leukemia and Lymphoma 2007, 48:584-595.
24. Kadowaki I., Ichinohasama R., Harigae H., Ishizawa K., Okitsu Y., Kameoka J., Sasaki T. Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C. British Journal of Haematology 2005, 130:869-877.
25. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
26. Koster A., van Krieken J.H., Mackenzie M.A., Schraders M., Borm G.F., van der Laak J.A., Leenders W., Hebeda K., Raemaekers J.M. Increased vascularization predicts favourable outcome in follicular lymphoma. Clinical Cancer Research 2005, 11:154-161.
27. MacDonald V.S., Thamm D.H., Kurzman I.D., Turek M.M., Vail D.M. Does l-asparaginase influence efficacy when added to standard CHOP protocol for dogs with lymphoma?. Journal of Veterinary Internal Medicine 2005, 19:732-736.
28. Matiasek L.A., Platt S.R., Adams V., Scase T.J., Keys D., Miller J., Adamo F., Long S., Matiasek K. Ki-67 and vascular endothelial growth factor expression in intracranial meningeomas in dogs. Journal of Veterinary Internal Medicine 2009, 23:146-151.
29. Millanta F., Silvestri G., Vaselli C., Citi S., Piansi G., Lorenzi D., Poli A. The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops. Research in Veterinary Science 2006, 81:350-357.
30. Moulton J.E., Harvey J.W. Tumors of lymphoid and hematopoietic tissue. Tumors of Domestic Animals 1990, 150-196. University of California Press, Berkely, California, USA. 3rd ed. J.E. Moulton (Ed.).
31. Paydas S., Seydaoglu G., Ergin M., Erdogan S., Yavuz S. The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas. Leukemia and Lymphoma 2009, 50:366-373.
32. Platt S.R., Scase T.J., Adams V., Wieczorek L., Miller J., Adamo F., Long S. Vascular endothelial growth factor expression in canine intracranial meningeomas and association with patient survival. Journal of Veterinary Internal Medicine 2006, 20:663-668.
33. Price G.S., Page R.L., Fischer B.M., Levine J.F., Gerig T.M. Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. Journal of Veterinary Internal Medicine 1991, 5:259-262.
34. Quinn T.P., Peters K.G., De Vries C., Ferrara N., Williams L.T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:7533-7537.
35. Rahimi N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Frontiers in Bioscience 2006, 11:818-829.
36. Rassnick K.M., McEntee M.C., Erb H.N., Burke B.P., Balkman C.E., Flory A.B., Kiselow M.A., Autio K., Gieger T.L. Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma. Journal of Veterinary Internal Medicine 2007, 21:1364-1373.
37. Restucci B., Papparella S., Maiolino P., De Vico G. Expression of vascular endothelial growth factor in canine mammary tumors. Veterinary Pathology 2002, 39:488-493.
38. Restucci B., Maiolino P., Paciello O., Martano M., De Vico G., Papparella S. Evaluation of angiogenesis in canine seminomas by quantitative immunohistochemistry. Journal of Comparative Pathology 2003, 128:252-259.
39. Restucci B., Borzacchiello G., Maiolino P., Martano M., Paciello O., Paparello S. Expression of vascular endothelial growth factor receptor Flk-1 in canine mammary tumours. Journal of Comparative Pathology 2004, 130:99-104.
40. Rini B.I. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer 2009, 15(Suppl. 10):2306-2312.
41. Roskoski R. VEGF receptor-tyrosine kinases: structure and regulation. Biochemical and Biophysical Research Communications 2008, 375:287-291.
42. Shibuya M. Differentia roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. Journal of Biochemistry and Molecular Biology 2006, 39:469-478.
43. Shiomitsu K., Johnson C.L., Malarkey D.E., Pruitt A.F., Thrall D.E. Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours. Veterinary and Comparative Oncology 2009, 7:106-114.
44. Taylor K.H., Smith A.N., Higginbotham M., Schwartz D.D., Carpenter D.M., Whitley E.M. Expression of vascular endothelial growth factor in canine oral malignant melanoma. Veterinary and Comparative Oncology 2007, 5:208-218.
45. Tonar Z., Egger G.F., Witter K., Wolfesberger B. Quantification of microvessels in canine lymph nodes. Microscopy Research and Technique 2008, 71:760-772.
46. Turley H., Scott P.A., Watts V.M., Bicknell R., Harris A.L., Gatter K.C. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. Journal of Pathology 1998, 186:313-318.
47. Tzankov A., Heiss S., Ebner S., Sterlacci W., Schaefer G., Augustin F., Fiegl M., Dirnhofer S. Angiogenesis in nodal B cell lymphomas: a high throughput study. Journal of Clinical Pathology 2007, 60:476-482.
48. Vail D.M., Young K.M. Canine Lymphoma and Lymphoid Leukemia 2007, 699-733. Saunders, St. Louis, Missouri. fourth ed. S.J. Withrow, D.M. Vail (Eds.).
49. Waltenberger J., Claesson, Welsh L., Siegbahn A., Shibuya M., Heldin C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. Journal of Biological Chemistry 1994, 269:26988-26995.
50. Wang E.S., Teruya-Feldstein J., Wu Y., Zhu Z., Hicklin D.J., Moore M.A. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004, 104:2893-2902.
51. Wolfesberger B., Guija de Arespacohaga A., Willmann M., Gerner W., Miller I., Schwendenwein I., Kleiter M., Egerbacher M., Thalhammer J.G., Muellauer L., Skalicky M., Walter I. Expression of vascular endothelial growth factor and its receptors in canine lymphomas. Journal of Comparative Pathology 2007, 137:30-40.
52. Wolfesberger B., Tonar Z., Witter K., Guija de Arespacohaga A., Skalicky M., Walter I., Thalhammer J.G., Egger G.F. Microvessel density in normal lymph nodes and lymphomas of dogs and their correlation with vascular endothelial growth factor expression. Research in Veterinary Science 2008, 85:56-61.
53. Yonemaru K., Sakai H., Murakami M., Yanai T., Masegi T. Expression of vascular endothelial growth factor, basic fibroblastic growth factor, and their receptors (flt-1, flk-1 and flg-1) in canine vascular tumors. Veterinary Pathology 2006, 43:971-980.